Drug General Information
Drug ID	D0O7DU
Former ID	DIB010501
Drug Name	CT-1746
Indication	Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]		Terminated	[546133]
Company	Celltech Therapeutics Ltd
Structure		Download 2D MOL 3D MOL
Canonical SMILES	N(C(=O)[C@@H](CC(=O)NO)CCCc1ccc(Cl)cc1)[C@@H](C(=O)N)C(<br />C)(C)C
CAS Number	CAS 162514-46-7
Target and Pathway
Target(s)	MMP-9	Target Info	Modulator	[534338]
KEGG Pathway	TNF signaling pathway
	Leukocyte transendothelial migration
	Estrogen signaling pathway
	Hepatitis B
	Pathways in cancer
	Transcriptional misregulation in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Bladder cancer
NetPath Pathway	ID Signaling Pathway
	TWEAK Signaling Pathway
	Leptin Signaling Pathway
	TNFalpha Signaling Pathway
PANTHER Pathway	Alzheimer disease-presenilin pathway
	Plasminogen activating cascade
	CCKR signaling map ST
Pathway Interaction Database	LPA receptor mediated events
	Plasma membrane estrogen receptor signaling
	Osteopontin-mediated events
	Validated transcriptional targets of AP1 family members Fra1 and Fra2
	Validated targets of C-MYC transcriptional activation
	CXCR4-mediated signaling events
	amb2 Integrin signaling
	Syndecan-4-mediated signaling events
	AP-1 transcription factor network
	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	Syndecan-1-mediated signaling events
	Regulation of nuclear beta catenin signaling and target gene transcription
	FGF signaling pathway
Reactome	Collagen degradation
	Degradation of the extracellular matrix
	Activation of Matrix Metalloproteinases
	Assembly of collagen fibrils and other multimeric structures
	EPH-ephrin mediated repulsion of cells
WikiPathways	Endochondral Ossification
	IL1 and megakaryotyces in obesity
	Mammary gland development pathway - Involution (Stage 4 of 4)
	Activation of Matrix Metalloproteinases
	Degradation of collagen
	Spinal Cord Injury
	AGE/RAGE pathway
	TWEAK Signaling Pathway
	Angiogenesis
	Osteopontin Signaling
	Matrix Metalloproteinases
References
Ref 546133	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006498)
Ref 534338	Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.